OncoMatch/Clinical Trials/NCT03326947

Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

Is NCT03326947 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies docetaxel, cisplatin and 5-fluorouracil for neoplasm neck.

Phase 2RecruitingShanghai Jiao Tong University School of MedicineNCT03326947Data as of Jun 2026Location: China

Treatment: docetaxel, cisplatin and 5-fluorouracil — To investigate the predictive value of stathmin expression as a predictive biomarker in OSCC patients, who treated with TPF (docetaxel, cisplatin and 5-fluorouracil ) induction chemotherapy followed by radical surgery and radiotherapy/chemoradiotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

docetaxel, cisplatin and 5-fluorouracil

Biomarker criteria

Required: STMN1 low expression (low)

Disease stage

Required: Stage III, IVA

Clinical stage III/IVA

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: surgery

Exception: diagnostic biopsy

Previous surgical procedure of the primary tumors or lymph nodes (except diagnostic biopsy)

Cannot have received: radiation therapy

Previous radiotherapy

Cannot have received: cytotoxic chemotherapy

Previous chemotherapy

Lab requirements

Blood counts

White blood cell >3,000/mm3, hemoglobin >8g/L, platelet count >80,000/mm3

Kidney function

Serum creatinine <1.5x ULN; creatinine clearance <30ml/min [excluded]

Liver function

ALAT/ASAT <2.5x ULN, bilirubin <1.5x ULN

White blood cell >3,000/mm3, hemoglobin>8g/L, platelet count>80,000/mm3. Hepatic function: ALAT/ASAT <2.5x ULN, bilirubin <1.5x ULN. Serum creatinine <1.5x ULN. Creatinine clearance <30ml/min [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT03326947 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Does this trial require STMN1?

Yes, STMN1 low expression is a required biomarker for enrollment.

What disease stage is eligible?

Stage III or IVA is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify